Equities analysts predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will post earnings of ($0.11) per share for the current quarter, Zacks reports. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.06). Collegium Pharmaceutical reported earnings of ($0.45) per share during the same quarter last year, which indicates a positive year over year growth rate of 75.6%. The firm is scheduled to issue its next earnings report on Wednesday, November 14th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.72) to ($0.49). For the next year, analysts anticipate that the company will post earnings of $0.60 per share, with EPS estimates ranging from $0.00 to $1.20. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.02. The firm had revenue of $73.10 million for the quarter, compared to analysts’ expectations of $72.21 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The company’s quarterly revenue was up 1930.6% compared to the same quarter last year.

A number of equities analysts recently weighed in on the company. BidaskClub raised Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday. Cantor Fitzgerald set a $35.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Friday, September 21st. HC Wainwright reissued a “buy” rating on shares of Collegium Pharmaceutical in a research note on Monday, September 17th. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, August 8th. Finally, Janney Montgomery Scott set a $27.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, August 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Collegium Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $31.71.

A number of large investors have recently added to or reduced their stakes in COLL. Millennium Management LLC grew its stake in Collegium Pharmaceutical by 1,171.8% during the 2nd quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock valued at $8,611,000 after acquiring an additional 332,647 shares in the last quarter. Summit Trail Advisors LLC grew its stake in Collegium Pharmaceutical by 2,221.9% during the 1st quarter. Summit Trail Advisors LLC now owns 332,708 shares of the specialty pharmaceutical company’s stock valued at $333,000 after acquiring an additional 318,379 shares in the last quarter. BlackRock Inc. grew its stake in Collegium Pharmaceutical by 13.8% during the 2nd quarter. BlackRock Inc. now owns 2,252,273 shares of the specialty pharmaceutical company’s stock valued at $53,717,000 after acquiring an additional 272,302 shares in the last quarter. Macquarie Group Ltd. grew its stake in Collegium Pharmaceutical by 9.9% during the 2nd quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock valued at $61,732,000 after acquiring an additional 233,598 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Collegium Pharmaceutical by 78.5% during the 2nd quarter. Northern Trust Corp now owns 526,499 shares of the specialty pharmaceutical company’s stock valued at $12,557,000 after acquiring an additional 231,463 shares in the last quarter. 93.57% of the stock is currently owned by institutional investors.

COLL traded up $0.41 during trading on Friday, reaching $17.08. The company had a trading volume of 638,574 shares, compared to its average volume of 530,798. The stock has a market capitalization of $489.69 million, a P/E ratio of -6.91 and a beta of 0.43. Collegium Pharmaceutical has a 12-month low of $9.01 and a 12-month high of $29.90. The company has a current ratio of 0.82, a quick ratio of 0.78 and a debt-to-equity ratio of 3.94.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Recommended Story: What does RSI mean?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.